- ￥300
- YOYOBIO
- 上海
- YJ-B21453-20mg
- 2025年12月23日
企业认证
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
2-8℃
- 保质期：
见包装
- 英文名：
Irinotecan hydrochloride
- 库存：
大量现货
- 供应商：
上海研谨生物
- CAS号：
100286-90-6
- 规格：
20mg
盐酸伊立替康
分析标准品,HPLC≥98%
Irinotecan hydrochloride
CAS号：100286-90-6
分子式：C33H38N4O6 · HCl
分子量：623.14
MDL：MFCD01862255
别名：盐酸依列替康;Topotecin; Irinotecan Hcl; CPT-11 hydrochloride; Campto hydrochloride; Camptothecin 11 hydrochloride; CPT 11; Camptothecin analog; Campto
|
货号 |
规格/参数/品牌 |
价格 |
货期 |
|
YJ-B21453-20mg |
分析标准品,HPLC≥98% |
￥300.00 |
现货 |
|
JS25911-250mg |
98% |
￥600.00 |
现货 |
|
JS25911-1g |
98% |
￥1200.00 |
现货 |
|
JS25911-5g |
98% |
￥3380.00 |
现货 |
产品介绍
熔点：250-256℃ (dec.)
沸点：257 ℃
比旋光度：67.7 ° (C=1, H2O)
外观：淡黄色粉末或淡黄色结晶性粉末
溶解性：在水、乙醇或氯仿中微溶，在丙tong中不溶
储存条件：2-8℃
注意：部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验参考文献(8篇)
8. [IF=6.8] Danyang Hu et al."Discovery of a Novel Serine-Targeting Covalent Inhibitor against HCES2A for Treating Drug-induced Diarrhea and Ulcerative Colitis."JOURNAL OF MEDICINAL CHEMISTRY.2025;XXXX(XXX):XXX-XXX
7. [IF=4.4] Yixuan Wang et al."Therapeutic potential of Astragalus membranaceus—Pueraria lobata decoction for the treatment of chemotherapy bowel injury."FASEB JOURNAL.2024 Oct;38(19):e70102
6. [IF=4.5] Hongyu Zhong et al."RBCs as a Bioinspired Drug Delivery System for Co-delivery of Irinotecan and Nanoalumina Enhances Colorectal Cancer Therapy."MOLECULAR PHARMACEUTICS.2025;XXXX(XXX):XXX-XXX
5. [IF=7.5] Jianzheng He et al."Irinotecan cause the side effects on development and adult physiology, and induces intestinal damage via innate immune response and oxidative damage in Drosophila."BIOMEDICINE & PHARMACOTHERAPY.2023 Dec;169:115906
4. [IF=3.841] Lu Wang et al."Binding of combined irinotecan and epicatechin to a pH-responsive DNA tetrahedron for controlled release and enhanced cytotoxicity."JOURNAL OF MOLECULAR STRUCTURE.2023 Jul;1283:135323
3. [IF=5.988] Wenbin Diao et al."PNA-Modified Liposomes Improve the Delivery Efficacy of CAPIRI for the Synergistic Treatment of Colorectal Cancer."Frontiers in Pharmacology.2022; 13: 893151
2. [IF=6.4] Ye Bi et al."Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy."Int J Nanomed. 2018; 13: 5811–5822
1. Bi, Ye, et al. "Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy." International journal of nanomedicine 13 (2018): 5811.https:##dx.doi.org/10.2147%2FIJN.S173279
技术资料暂无技术资料 索取技术资料
